Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Mass Balance Study of [14C] HMPL-453 in Healthy Chinese Adult Male Subjects
NCT07644442Phase 1Completed
- Sponsor
- HUTCHMED
- Start
- Feb 2025
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fanregratinib, sponsored by HUTCHMED. Primary endpoints: Human Mass balance, Radioactive metabolite profile and 1 more. Started Feb 2025; status: completed.
02
Drugs
fanregratinib
Beyond the preview
Go deeper on NCT07644442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07644442.